Shockwave Medical has announced the completion of enrolment in EMPOWER CAD, the first prospective all-female study of percutaneous coronary intervention (PCI) in complex calcific disease.
The study is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and patients will subsequently be followed out to three years.
“The completion of enrolment in EMPOWER CAD is a major milestone in our desire to improve cardiovascular outcomes for women with challenging calcified lesions,” said Margaret McEntegart (Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, USA), co-principal investigator of EMPOWER CAD. “Not only will this study yield valuable insights on the performance of coronary IVL in female patients, but as the first prospective all-comers study of coronary IVL, we also hope to gain additional insights about the utility of the technology in more complex patients.”
Women have traditionally been underrepresented in cardiovascular clinical trials, comprising only around a quarter of enrolled patients in many studies1 and only a tenth of trial leadership committees. Such underrepresentation for female patients in coronary artery disease studies has led to a lack of actionable gender-specific data to drive improved outcomes, even though women undergoing PCI have a higher risk of procedural complications than men.
“We are eager to analyse the data and share results next year, with a goal of helping to close the gap in treatment outcomes between men and women,” said Alexandra Lansky (Yale University School of Medicine, New Haven, USA) and co-principal investigator of EMPOWER CAD. “EMPOWER represents a significant step forward in women’s heart health. We also look forward to seeing the participating female interventional cardiologists and clinical researchers in the study continue to take on clinical trial leadership roles in the years to come.”
The EMPOWER CAD study enrolled 400 participants across 48 sites, spanning five countries, completing enrolment during a live case by McEntegart at the TCT Conference in Washington DC, USA.
Notably, 71% of the enrolling sites were led by female principal investigators, underscoring the study’s commitment to diversity and leadership in clinical research. The study’s European lead is Nieves Gonzalo (Hospital Clinico San Carlos in Madrid, Spain).
